Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children

Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the con...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera, Natalia, Duquesne, Agnes, Desjonquères, Marine, Larbre, Jean-Paul, Lega, Jean-Christophe, Fabien, Nicole, Belot, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Paediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030575/
https://www.ncbi.nlm.nih.gov/pubmed/27738519
http://dx.doi.org/10.1136/rmdopen-2016-000271
Descripción
Sumario:Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the context of connective tissue disease. However, in both cases, other systemic autoimmune symptoms were not modified by the treatment and autoantibodies tend to increase, suggesting a differential effect of IL-6 inhibition on articular inflammation and systemic autoimmunity.

Ejemplares similares